Sarah Davis

8.3k total citations · 1 hit paper
112 papers, 3.7k citations indexed

About

Sarah Davis is a scholar working on Surgery, Orthopedics and Sports Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sarah Davis has authored 112 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Surgery, 19 papers in Orthopedics and Sports Medicine and 18 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sarah Davis's work include Bone health and osteoporosis research (16 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Sarah Davis is often cited by papers focused on Bone health and osteoporosis research (16 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Sarah Davis collaborates with scholars based in United Kingdom, United States and Canada. Sarah Davis's co-authors include Matt Stevenson, Darrow E. Haagensen, Gwen Mazoujian, Thomas W. Pendergrass, Geraldine S. Pinkus, Noel R. Rose, DeLisa Fairweather, Sylvia Frisancho‐Kiss, Masheka A. Barrett and Emma Simpson and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sarah Davis

106 papers receiving 3.6k citations

Hit Papers

Pyroptosis is a critical inflammatory pathway in the plac... 2019 2026 2021 2023 2019 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors
    2019 183 citations Shi‐Bin Cheng, Akitoshi Nakashima et al. Cell Death and Disease profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah Davis United Kingdom 30 789 752 559 509 487 112 3.7k
Eisuke Inoue Japan 39 509 0.6× 546 0.7× 626 1.1× 259 0.5× 161 0.3× 233 5.5k
Robert A. Wild United States 46 498 0.6× 952 1.3× 1.3k 2.3× 179 0.4× 1.6k 3.4× 204 10.4k
José António Pereira da Silva Portugal 40 438 0.6× 523 0.7× 689 1.2× 471 0.9× 179 0.4× 265 7.6k
José L. Hernández Spain 35 487 0.6× 680 0.9× 734 1.3× 755 1.5× 284 0.6× 308 4.4k
Josée Dupuis United States 44 440 0.6× 2.0k 2.7× 831 1.5× 265 0.5× 753 1.5× 199 6.9k
Esa Läärä Finland 37 1.2k 1.5× 694 0.9× 2.4k 4.4× 210 0.4× 465 1.0× 129 8.3k
Giancarlo Isaia Italy 39 1.7k 2.1× 1.8k 2.3× 700 1.3× 1.9k 3.7× 177 0.4× 168 5.2k
David H. Barad United States 55 449 0.6× 1.1k 1.5× 374 0.7× 163 0.3× 238 0.5× 270 10.0k
Celia M.T. Greenwood Canada 45 692 0.9× 2.8k 3.7× 609 1.1× 369 0.7× 344 0.7× 217 8.2k
Serge Rozenberg Belgium 41 855 1.1× 691 0.9× 629 1.1× 1.1k 2.1× 64 0.1× 227 5.0k

Countries citing papers authored by Sarah Davis

Since Specialization
Citations

This map shows the geographic impact of Sarah Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah Davis more than expected).

Fields of papers citing papers by Sarah Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah Davis. The network helps show where Sarah Davis may publish in the future.

Co-authorship network of co-authors of Sarah Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah Davis. A scholar is included among the top collaborators of Sarah Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah Davis. Sarah Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Horner, Daniel, Sarah Davis, Abdullah Pandor, et al.. (2024). Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis. Health Technology Assessment. 28(20). 1–166. 3 indexed citations
2.
Davis, Sarah, Steve Goodacre, Daniel Horner, et al.. (2024). Effectiveness and cost effectiveness of pharmacological thromboprophylaxis for medical inpatients: decision analysis modelling study. SHILAP Revista de lepidopterología. 3(1). e000408–e000408. 3 indexed citations
3.
Guthrie, Bruce, G Rogers, Shona Livingstone, et al.. (2024). The implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis. SHILAP Revista de lepidopterología. 12(4). 1–275. 2 indexed citations
4.
Paskins, Zoé, Anastasios Bastounis, Sarah Davis, et al.. (2023). Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise. Osteoporosis International. 34(10). 1711–1718. 1 indexed citations
5.
Sahota, Opinder, Melanie Narayanasamy, Anastasios Bastounis, et al.. (2023). Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study. Health Technology Assessment. 28(21). 1–169. 2 indexed citations
6.
Cox, Alison D., Sarah Davis, & Maurice A. Feldman. (2022). Medication training for behavior analysts.. Behavior Analysis Research and Practice. 22(1). 130–142. 1 indexed citations
7.
Bastounis, Anastasios, Tessa Langley, Sarah Davis, et al.. (2022). Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis. Osteoporosis International. 33(6). 1223–1233. 7 indexed citations
8.
Pandor, Abdullah, Jahnavi Daru, Beverley J. Hunt, et al.. (2022). Risk assessment models for venous thromboembolism in pregnancy and in the puerperium: a systematic review. BMJ Open. 12(10). e065892–e065892. 6 indexed citations
9.
Davis, Sarah, Emma Simpson, Jean Hamilton, et al.. (2020). Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation. Health Technology Assessment. 24(29). 1–314. 89 indexed citations
10.
Simpson, Emma, Marrissa Martyn‐St James, Jean Hamilton, et al.. (2019). Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis. Bone. 130. 115081–115081. 50 indexed citations
11.
Cheng, Shi‐Bin, Akitoshi Nakashima, Warren J. Huber, et al.. (2019). Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors. Cell Death and Disease. 10(12). 927–927. 183 indexed citations breakdown →
12.
Pandor, Abdullah, Daniel Horner, Sarah Davis, et al.. (2019). Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. Health Technology Assessment. 23(63). 1–190. 22 indexed citations
13.
Davis, Sarah, Rachid Rafia, Christopher Carroll, Jean Hamilton, & Munira Essat. (2018). Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 37(6). 763–775. 5 indexed citations
14.
Davis, Sarah, Marrissa Martyn‐St James, Jean Sanderson, et al.. (2016). A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technology Assessment. 20(78). 1–406. 57 indexed citations
15.
Walklet, Elaine, Sarah Davis, Daniel Farrelly, & Kate Muse. (2016). The impact of Student Response Systems on the learning experience of undergraduate psychology students. Psychology Teaching Review. 22(1). 35–48. 9 indexed citations
16.
Karnon, Jonathan, Carolyn Czoski‐Murray, Kenneth J. Smith, et al.. (2008). A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration. Health Technology Assessment. 12(27). iii–iv, ix. 23 indexed citations
17.
Fairweather, DeLisa, Sylvia Frisancho‐Kiss, Dolores B. Njoku, et al.. (2006). Complement Receptor 1 and 2 Deficiency Increases Coxsackievirus B3-Induced Myocarditis, Dilated Cardiomyopathy, and Heart Failure by Increasing Macrophages, IL-1β, and Immune Complex Deposition in the Heart. The Journal of Immunology. 176(6). 3516–3524. 59 indexed citations
18.
19.
Fairweather, DeLisa, Sylvia Frisancho‐Kiss, Susy Yusung, et al.. (2005). IL-12 Protects against Coxsackievirus B3-Induced Myocarditis by Increasing IFN-γ and Macrophage and Neutrophil Populations in the Heart. The Journal of Immunology. 174(1). 261–269. 113 indexed citations
20.
Davis, Sarah. (1992). Bulgur comes into its own.. 46(6). 112–112.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eisuke Inoue Breakdown of academic impact, for papers by Robert A. Wild Breakdown of academic impact, for papers by José António Pereira da Silva Breakdown of academic impact, for papers by José L. Hernández Breakdown of academic impact, for papers by Josée Dupuis Breakdown of academic impact, for papers by Esa Läärä Breakdown of academic impact, for papers by Giancarlo Isaia Breakdown of academic impact, for papers by David H. Barad Breakdown of academic impact, for papers by Celia M.T. Greenwood Breakdown of academic impact, for papers by Serge Rozenberg
Rankless by CCL
2026